Management of Chronic Pain in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline.

PURPOSE To provide evidence-based guidance on the optimum management of chronic pain in adult cancer survivors. METHODS An ASCO-convened expert panel conducted a systematic literature search of studies investigating chronic pain management in cancer survivors. Outcomes of interest included symptom relief, pain intensity, quality of life, functional outcomes, adverse events, misuse or diversion, and risk assessment or mitigation. RESULTS A total of 63 studies met eligibility criteria and compose the evidentiary basis for the recommendations. Studies tended to be heterogeneous in terms of quality, size, and populations. Primary outcomes also varied across the studies, and in most cases, were not directly comparable because of different outcomes, measurements, and instruments used at different time points. Because of a paucity of high-quality evidence, many recommendations are based on expert consensus. RECOMMENDATIONS Clinicians should screen for pain at each encounter. Recurrent disease, second malignancy, or late-onset treatment effects in any patient who reports new-onset pain should be evaluated, treated, and monitored. Clinicians should determine the need for other health professionals to provide comprehensive pain management care in patients with complex needs. Systemic nonopioid analgesics and adjuvant analgesics may be prescribed to relieve chronic pain and/or to improve function. Clinicians may prescribe a trial of opioids in carefully selected patients with cancer who do not respond to more conservative management and who continue to experience distress or functional impairment. Risks of adverse effects of opioids should be assessed. Clinicians should clearly understand terminology such as tolerance, dependence, abuse, and addiction as it relates to the use of opioids and should incorporate universal precautions to minimize abuse, addiction, and adverse consequences. Additional information is available at www.asco.org/chronic-pain-guideline and www.asco.org/guidelineswiki.

[1]  Bonnie Spring,et al.  Meta-analysis of psychosocial interventions to reduce pain in patients with cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  D. Foster,et al.  Opioid pharmacokinetic drug-drug interactions. , 2011, The American journal of managed care.

[3]  Penny F Whiting,et al.  Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. , 2015, JAMA.

[4]  Edward S. Lee,et al.  Racial disparities in the monitoring of patients on chronic opioid therapy , 2013, PAIN®.

[5]  P. Fayers,et al.  A systematic review of oxymorphone in the management of chronic pain. , 2010, Journal of pain and symptom management.

[6]  K. Kwekkeboom,et al.  Mind-body treatments for the pain-fatigue-sleep disturbance symptom cluster in persons with cancer. , 2010, Journal of pain and symptom management.

[7]  S. Butler,et al.  Development and validation of the Current Opioid Misuse Measure , 2007, PAIN.

[8]  R. Portenoy Treatment of cancer pain , 2011, The Lancet.

[9]  Howard S. Smith,et al.  Evidence-based medicine, systematic reviews, and guidelines in interventional pain management: Part 2: Randomized controlled trials. , 2008, Pain physician.

[10]  P. Oh,et al.  [Meta-analysis of psychosocial interventions to reduce pain in patients with cancer]. , 2013, Journal of Korean Academy of Nursing.

[11]  P. Moorman,et al.  The evidence for pharmacologic treatment of neuropathic cancer pain: beneficial and adverse effects. , 2013, Journal of pain and symptom management.

[12]  R. Malekzadeh,et al.  Opium: An emerging risk factor for gastric adenocarcinoma , 2013, International journal of cancer.

[13]  H. Cabral,et al.  Clinical factors associated with prescription drug use disorder in urban primary care patients with chronic pain. , 2010, The journal of pain : official journal of the American Pain Society.

[14]  H. Mead,et al.  Racial and Ethnic Disparities in U.S. Health Care: A Chartbook , 2008 .

[15]  J. Armer,et al.  Mindfulness-based stress reduction among breast cancer survivors: a literature review and discussion. , 2011, Oncology nursing forum.

[16]  Leonard J Paulozzi,et al.  Prescription drug monitoring programs and death rates from drug overdose. , 2011, Pain medicine.

[17]  Roger Chou,et al.  CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016. , 2016, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[18]  D. Grobbee,et al.  Long-term effects on cancer survivors’ quality of life of physical training versus physical training combined with cognitive-behavioral therapy: results from a randomized trial , 2009, Supportive Care in Cancer.

[19]  M. Sullivan,et al.  The missing 'P' in pain management: how the current opioid epidemic highlights the need for psychiatric services in chronic pain care. , 2014, General hospital psychiatry.

[20]  M. Ware,et al.  Cannabinoids for the Treatment of Chronic Non-Cancer Pain: An Updated Systematic Review of Randomized Controlled Trials , 2015, Journal of Neuroimmune Pharmacology.

[21]  M. Taylor The impact of the "business" of pain medicine on patient care. , 2011, Pain medicine.

[22]  M. Arroyo-Morales,et al.  Effectiveness of water physical therapy on pain, pressure pain sensitivity, and myofascial trigger points in breast cancer survivors: a randomized, controlled clinical trial. , 2012, Pain medicine.

[23]  R. Dworkin,et al.  Ketamine for pain in adults and children with cancer: a systematic review and synthesis of the literature. , 2013, Pain medicine.

[24]  T. Hart-Johnson,et al.  Cancer‐related chronic pain , 2011, Cancer.

[25]  R. Chou,et al.  CDC Guideline for Prescribing Opioids for Chronic Pain--United States, 2016. , 2016, JAMA.

[26]  M. Tramèr,et al.  Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review , 2001, BMJ : British Medical Journal.

[27]  E. Ernst,et al.  Acupuncture for the treatment of cancer pain: a systematic review of randomised clinical trials , 2012, Supportive Care in Cancer.

[28]  M. Stubblefield,et al.  Pain in cancer survivors. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  K. Schechtman,et al.  Balloon kyphoplasty versus non-surgical fracture management for treatment of painful vertebral body compression fractures in patients with cancer: a multicentre, randomised controlled trial. , 2011, The Lancet. Oncology.

[30]  R. Zachariae,et al.  The efficacy of psychosocial intervention for pain in breast cancer patients and survivors: a systematic review and meta-analysis , 2013, Breast Cancer Research and Treatment.

[31]  K. Lange,et al.  Preoperative and postoperative cognitive functioning in patients with frontal meningiomas. , 2003, Journal of neurosurgery.

[32]  L. Campbell,et al.  The unequal burden of pain: confronting racial and ethnic disparities in pain. , 2003, Pain medicine.

[33]  K. Syrjala,et al.  Measuring musculoskeletal symptoms in cancer survivors who receive hematopoietic cell transplantation , 2010, Journal of cancer survivorship : research and practice.

[34]  S. Schnoll,et al.  Do prescription monitoring programs impact state trends in opioid abuse/misuse? , 2012, Pain medicine.

[35]  Hans Hansen,et al.  American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part 2--guidance. , 2012, Pain physician.

[36]  J. Kramer Medical marijuana for cancer , 2015, CA: a cancer journal for clinicians.

[37]  Jeanmarie Perrone,et al.  Can prescription drug monitoring programs help limit opioid abuse? , 2011, JAMA.

[38]  B. Felker,et al.  Comorbid Psychiatric Disorders and Predictors of Pain Management Program Success in Patients With Chronic Pain. , 2002, Primary care companion to the Journal of clinical psychiatry.

[39]  L. Gustafsson,et al.  Cytochrome P450-Mediated Changes in Oxycodone Pharmacokinetics/Pharmacodynamics and Their Clinical Implications , 2013, Drugs.

[40]  D. Alford Opioid Prescribing for Chronic Pain--Achieving the Right Balance through Education. , 2016, The New England journal of medicine.

[41]  B. Storer,et al.  Late effects of hematopoietic cell transplantation among 10-year adult survivors compared with case-matched controls. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  E. Kravitz,et al.  Intrathecal opioid treatment for chronic non-malignant pain: a 3-year prospective study , 2004, Pain.

[43]  Sabita Roy,et al.  Role of the mu-opioid receptor in opioid modulation of immune function , 2013, Amino Acids.

[44]  Todd M. Moore,et al.  Validation of a new risk assessment tool: the Brief Risk Questionnaire. , 2015, Journal of opioid management.

[45]  E. Bruera,et al.  Association between hypogonadism, symptom burden, and survival in male patients with advanced cancer , 2014, Cancer.

[46]  E. Kalso,et al.  Ketamine as an adjuvant to opioids for cancer pain. , 2017, The Cochrane database of systematic reviews.

[47]  J. Kleijnen,et al.  Systematic review of tapentadol in chronic severe pain , 2011, Current medical research and opinion.

[48]  R. Kulich,et al.  Tapering Long-term Opioid Therapy in Chronic Noncancer Pain: Evidence and Recommendations for Everyday Practice. , 2015, Mayo Clinic proceedings.

[49]  Matt Schiller,et al.  Analytic models to identify patients at risk for prescription opioid abuse. , 2009, The American journal of managed care.

[50]  E. Bruera,et al.  A systematic review of randomized trials on the effectiveness of opioids for cancer pain. , 2012, Pain physician.

[51]  B. Turner,et al.  Systematic Review: Treatment Agreements and Urine Drug Testing to Reduce Opioid Misuse in Patients With Chronic Pain , 2010, Annals of Internal Medicine.

[52]  S. J. Henley,et al.  Invasive Cancer Incidence and Survival--United States, 2012. , 2015, MMWR. Morbidity and mortality weekly report.

[53]  F. Janku,et al.  The mu opioid receptor: A new target for cancer therapy? , 2015, Cancer.

[54]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[55]  J. Collet,et al.  Cannabis for the Management of Pain: Assessment of Safety Study (COMPASS). , 2015, The journal of pain : official journal of the American Pain Society.

[56]  P. Wiffen,et al.  Antidepressants for neuropathic pain: a Cochrane review , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[57]  R. Moore,et al.  Topical capsaicin (low concentration) for chronic neuropathic pain in adults , 2013, The Cochrane database of systematic reviews.

[58]  Mark I. Johnson,et al.  Transcutaneous electric nerve stimulation (TENS) for cancer pain in adults. , 2008, The Cochrane database of systematic reviews.

[59]  G. Keller,et al.  Other drugs acting on nervous system associated with QT-interval prolongation. , 2010, Current drug safety.

[60]  Dawn L Hershman,et al.  Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  A. Caraceni,et al.  The role of paracetamol and nonsteroidal anti-inflammatory drugs in addition to WHO Step III opioids in the control of pain in advanced cancer. A systematic review of the literature , 2012, Palliative medicine.

[62]  R. Portenoy,et al.  Principles of opioid use in cancer pain. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  R. Fillingim,et al.  Chronic pain management: nonpharmacological therapies for chronic pain. , 2015, FP essentials.

[64]  L. Manchikanti,et al.  Does adherence monitoring reduce controlled substance abuse in chronic pain patients? , 2006, Pain physician.

[65]  S. Kaasa,et al.  Do corticosteroids provide analgesic effects in cancer patients? A systematic literature review. , 2013, Journal of pain and symptom management.

[66]  J. Ligibel Physical activity for cancer survivors: meta-analysis of randomised controlled trials: Fong DYT, Ho JWC, Hui BPH, et al (Univ of Hong Kong, China; Hong Kong Polytechnic Univ, Hung Hom, Kowloon; et al) BMJ 344:e70, 2012§ , 2012 .

[67]  V. Sheppard,et al.  Race, Ethnicity, and Pain among the U.S. Adult Population , 2010, Journal of health care for the poor and underserved.

[68]  N. Lurie,et al.  Racial and Ethnic Disparities in Care: The Perspectives of Cardiologists , 2005, Circulation.

[69]  R. Moore,et al.  Topical capsaicin (low concentration) for chronic neuropathic pain in adults. , 2012, The Cochrane database of systematic reviews.

[70]  Ernst T. Bohlmeijer,et al.  Acceptance-based interventions for the treatment of chronic pain: A systematic review and meta-analysis , 2011, PAIN®.

[71]  G. Hanks,et al.  A systematic review of oxycodone in the management of cancer pain , 2011, Palliative medicine.

[72]  Mark I. Johnson,et al.  Acupuncture for cancer pain in adults. , 2011, The Cochrane database of systematic reviews.

[73]  M. Arroyo-Morales,et al.  Effectiveness of a Multidimensional Physical Therapy Program on Pain, Pressure Hypersensitivity, and Trigger Points in Breast Cancer Survivors: A Randomized Controlled Clinical Trial , 2012, The Clinical journal of pain.

[74]  J. McQuade,et al.  Systematic review of acupuncture in cancer care: a synthesis of the evidence. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  K. Ahrar,et al.  Percutaneous vertebroplasty and kyphoplasty for painful vertebral body fractures in cancer patients. , 2003, Journal of neurosurgery.

[76]  R. Dart,et al.  Trends in opioid analgesic abuse and mortality in the United States. , 2015, The New England journal of medicine.

[77]  Joseph A Boscarino,et al.  Risk factors for drug dependence among out-patients on opioid therapy in a large US health-care system. , 2010, Addiction.

[78]  D. Hochstrasser,et al.  The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone , 2010, British journal of pharmacology.

[79]  M. Davidsen,et al.  The Danish National Cohort Study (DANCOS) , 2003, Scandinavian journal of public health.

[80]  Diane D. Liu,et al.  Patterns of storage, use, and disposal of opioids among cancer outpatients. , 2014, The oncologist.

[81]  G. Bar-Sela,et al.  A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain , 2012, Palliative medicine.

[82]  J. Mossey Defining Racial and Ethnic Disparities in Pain Management , 2011, Clinical orthopaedics and related research.

[83]  D. Brizel,et al.  National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology , 2012 .

[84]  F. Chung,et al.  Chronic Opioid Use and Central Sleep Apnea: A Review of the Prevalence, Mechanisms, and Perioperative Considerations , 2015, Anesthesia and analgesia.

[85]  Todd M. Moore,et al.  Preliminary data on a new opioid risk assessment measure: the Brief Risk Interview. , 2013, Journal of opioid management.

[86]  Howard S. Smith,et al.  American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part I--evidence assessment. , 2012, Pain physician.

[87]  David Moher,et al.  Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews , 2007, BMC medical research methodology.

[88]  P. Sacerdote,et al.  Non-analgesic effects of opioids: mechanisms and potential clinical relevance of opioid-induced immunodepression. , 2012, Current pharmaceutical design.

[89]  Laura M J Hochstenbach,et al.  Update on Prevalence of Pain in Patients With Cancer: Systematic Review and Meta-Analysis. , 2016, Journal of pain and symptom management.

[90]  Frank Cirrone,et al.  Vismodegib and the hedgehog pathway: a new treatment for basal cell carcinoma. , 2012, Clinical therapeutics.

[91]  T. Jensen,et al.  The evidence for pharmacological treatment of neuropathic pain , 2010, PAIN.

[92]  B. Kapur,et al.  Methadone: a review of drug-drug and pathophysiological interactions , 2011, Critical reviews in clinical laboratory sciences.

[93]  S. Butler,et al.  Validation of a screener and opioid assessment measure for patients with chronic pain , 2004, Pain.

[94]  M. Fallon,et al.  Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. , 2010, Journal of pain and symptom management.

[95]  Diane C. Calleson,et al.  Racial differences in opioid use for chronic nonmalignant pain , 2005, Journal of General Internal Medicine.

[96]  M. Jensen,et al.  PALLIATIVE CARE SECTION Original Research Article Pain in Long-Term Breast Cancer Survivors: Frequency, Severity, and Impact , 2010 .

[97]  P. Christo,et al.  The influence of prescription monitoring programs on chronic pain management. , 2009, Pain physician.

[98]  H. Heit,et al.  Universal precautions in pain medicine: a rational approach to the treatment of chronic pain. , 2005, Pain medicine.

[99]  G. Pasternak,et al.  Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. , 2009, The journal of pain : official journal of the American Pain Society.

[100]  A. Ho,et al.  Thoracic Paravertebral Block and Its Effects on Chronic Pain and Health-Related Quality of Life After Modified Radical Mastectomy , 2014, Regional Anesthesia & Pain Medicine.

[101]  S. Rogers,et al.  Exercise interventions on health‐related quality of life for cancer survivors , 2012, Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery.

[102]  M. Lynch,et al.  Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. , 2011, British journal of clinical pharmacology.

[103]  M. Bennett Effectiveness of antiepileptic or antidepressant drugs when added to opioids for cancer pain: systematic review , 2011, Palliative medicine.

[104]  S. Carrara,et al.  Celiac plexus block for pancreatic cancer pain in adults. , 2011, The Cochrane database of systematic reviews.

[105]  D. Yee,et al.  Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signaling and promotes breast tumor growth. , 2002, Cancer research.

[106]  Sung-Hoon Kim,et al.  Meta-Analysis of Massage Therapy on Cancer Pain , 2015, Integrative cancer therapies.

[107]  C. Brunelli,et al.  Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[108]  T. Siegal,et al.  Cisplatin‐induced peripheral neuropathy. Frequent off‐therapy deterioration, demyelinating syndromes, and muscle cramps , 1990, Cancer.

[109]  B. Wilsey,et al.  Inhaled Cannabis for Chronic Neuropathic Pain: A Meta-analysis of Individual Patient Data. , 2015, The journal of pain : official journal of the American Pain Society.

[110]  Duncan J Macfarlane,et al.  Physical activity for cancer survivors: meta-analysis of randomised controlled trials , 2012, BMJ : British Medical Journal.

[111]  G. Wilkie,et al.  Medical Marijuana Use in Oncology: A Review. , 2016, JAMA oncology.

[112]  Richard N Shiffman,et al.  Building better guidelines with BRIDGE-Wiz: development and evaluation of a software assistant to promote clarity, transparency, and implementability , 2012, J. Am. Medical Informatics Assoc..

[113]  W. Ouyang,et al.  Regulatory T cells: a possible promising approach to cancer recurrence induced by morphine. , 2013, Medical hypotheses.

[114]  A. Caraceni,et al.  The role of hydromorphone in cancer pain treatment: a systematic review , 2011, Palliative medicine.

[115]  S. Butler,et al.  Validation of the revised Screener and Opioid Assessment for Patients with Pain (SOAPP-R). , 2008, The journal of pain : official journal of the American Pain Society.

[116]  L. Manchikanti,et al.  A comprehensive review of opioid-induced hyperalgesia. , 2011, Pain physician.

[117]  L. Webster,et al.  Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool. , 2005, Pain medicine.

[118]  P. Wiffen,et al.  Gabapentin for chronic neuropathic pain and fibromyalgia in adults. , 2011, The Cochrane database of systematic reviews.

[119]  R. Salgia,et al.  The Mu Opioid Receptor Promotes Opioid and Growth Factor-Induced Proliferation, Migration and Epithelial Mesenchymal Transition (EMT) in Human Lung Cancer , 2014, PloS one.

[120]  S. J. Henley,et al.  Invasive Cancer Incidence and Survival — United States, 2011 , 2015, MMWR. Morbidity and mortality weekly report.